Enrichment and characterization of human corneal endothelial cells (hCENC) with novel monoclonal antibody
US10287547B2 · kind B2 · utility
3Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 11, 2014 |
| Grant date | May 14, 2019 |
| Priority date | — |
| Expiry date | Apr 11, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/33
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.